SetPoint Medical of Santa Clarita has secured a $15 million investment in its pioneering biomedical treatment for inflammatory diseases such rheumatoid arthritis and Crohn’s Disease, the company announced today.
Proceeds will be used to help finance clinical trials, moving its biomedical device further along on the path towards commercialization.
“We’re building a device that’s like a miniature pacemaker for the immune system. It’s implanted in the body and can modulate, or turn down, the level of inflammation in the body,” said CEO Anthony Arnold.
The implant releases a small electronic stimulus once daily, for only one to two minutes, slowing the body from attacking itself in cases of chronic diseases where inflammation has become routine.
In essence, the device signals a nerve to turn inflammatory process way down.
What we’re doing is say ‘hey, call off the attack,’ ” Arnold said.
Conceivably, SetPoint’s treatment could replace costly medications currently on the market to treat inflammatory diseases.
Of the investors in this round of funding, the Valencia-based firm attracted a new, strategic investor but is not allowed to disclose the identity.
It also received stepped up support from an existing investor Action Potential Venture Capital, a GSK (GlaxoSmithKline) venture fund. As a result Juan-Pablo Mas of APVC is joining SetPoint’s Board of Directors.
“We have four major strategic investors. Three are in the medical device field and one in the pharmaceutical world,” Arnold said. “It signals confidence in our progress and moving forward.”
The latest round financing is the second largest the firm has received, he said. SetPoint received $28 million in 2013 when access to venture capital had dwindled for other firms as a result of the recession.
“SetPoint’s progress to date has been impressive, with promising data showing the potential of bioelectronic medicine as a revolutionary new way to treat diseases without drugs, using the body’s own systems,” said Juan-Pablo Mas, Partner of Action Potential Venture Capital in a prepared statement.
“We look forward to working with SetPoint to help fulfill this potential to deliver innovative treatments for rheumatoid arthritis, Crohn’s disease and other autoimmune and inflammatory diseases,” he said.

